Amicus Therapeutics, Inc. (NASDAQ:FOLD) Insider Ellen Rosenberg Sells 31,839 Shares

Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Rating) insider Ellen Rosenberg sold 31,839 shares of the stock in a transaction on Tuesday, January 24th. The stock was sold at an average price of $13.32, for a total value of $424,095.48. Following the transaction, the insider now directly owns 332,345 shares in the company, valued at approximately $4,426,835.40. The transaction was disclosed in a filing with the SEC, which is available at this link.

Amicus Therapeutics Stock Down 1.3 %

FOLD stock traded down $0.17 during trading on Wednesday, reaching $13.22. 1,303,502 shares of the company traded hands, compared to its average volume of 2,343,194. Amicus Therapeutics, Inc. has a 12 month low of $5.91 and a 12 month high of $13.61. The business has a 50 day simple moving average of $12.02 and a 200 day simple moving average of $11.36. The company has a market capitalization of $3.71 billion, a price-to-earnings ratio of -14.37 and a beta of 0.88. The company has a debt-to-equity ratio of 2.95, a quick ratio of 2.70 and a current ratio of 2.78.

Amicus Therapeutics (NASDAQ:FOLD – Get Rating) last released its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.07. Amicus Therapeutics had a negative return on equity of 123.94% and a negative net margin of 81.65%. The company had revenue of $81.69 million during the quarter, compared to analysts’ expectations of $84.55 million. On average, equities research analysts anticipate that Amicus Therapeutics, Inc. will post -0.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Amicus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Park Avenue Securities LLC purchased a new stake in Amicus Therapeutics in the fourth quarter valued at about $129,000. Wedge Capital Management L L P NC purchased a new stake in Amicus Therapeutics in the fourth quarter valued at about $2,795,000. Fulton Bank N.A. purchased a new stake in Amicus Therapeutics in the fourth quarter valued at about $144,000. Bank of New York Mellon Corp raised its stake in shares of Amicus Therapeutics by 4.8% in the third quarter. Bank of New York Mellon Corp now owns 1,229,564 shares of the biopharmaceutical company’s stock worth $12,837,000 after purchasing an additional 55,838 shares during the last quarter. Finally, Ambassador Advisors LLC purchased a new position in shares of Amicus Therapeutics in the third quarter worth about $3,301,000.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. BTIG Research increased their price target on Amicus Therapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Wednesday, January 18th. Morgan Stanley increased their price target on Amicus Therapeutics from $14.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 8th. Finally, StockNews.com raised Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, December 31st. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Amicus Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $15.00.

About Amicus Therapeutics

(Get Rating)

Amicus Therapeutics, Inc operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio.